Literature DB >> 17540734

Toll-like receptor 4 (TLR4)-dependent proinflammatory and immunomodulatory properties of the glycoinositolphospholipid (GIPL) from Trypanosoma cruzi.

Monica M Medeiros1, Jaqueline R Peixoto, Ana-Carolina Oliveira, Larissa Cardilo-Reis, Vera L G Koatz, Luc Van Kaer, José O Previato, Lúcia Mendonça-Previato, Alberto Nobrega, Maria Bellio.   

Abstract

We have demonstrated recently that the glycoinositolphospholipid (GIPL) molecule from the protozoan Trypanosoma cruzi is a TLR4 agonist with proinflammatory effects. Here, we show that GIPL-induced neutrophil recruitment into the peritoneal cavity is mediated by at least two pathways: one, where IL-1beta acts downstream of TNF-alpha, and a second, which is IL-1beta- and TNFRI-independent. Moreover, NKT cells participate in this proinflammatory cascade, as in GIPL-treated CD1d(-/-) mice, TNF-alpha and MIP-2 levels are reduced significantly. As a consequence of this inflammatory response, spleen and lymph nodes of GIPL-treated mice have an increase in the percentage of T and B cells expressing the CD69 activation marker. Cell-transfer experiments demonstrate that T and B cell activation by GIPL is an indirect effect, which relies on the expression of TLR4 by other cell types. Moreover, although signaling through TNFRI contributes to the activation of B and gammadelta+ T cells, it is not required for increasing CD69 expression on alphabeta+ T lymphocytes. It is interesting that T cells are also functionally affected by GIPL treatment, as spleen cells from GIPL-injected mice show enhanced production of IL-4 following in vitro stimulation by anti-CD3. Together, these results contribute to the understanding of the inflammatory properties of the GIPL molecule, pointing to its potential role as a parasite-derived modulator of the immune response during T. cruzi infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17540734     DOI: 10.1189/jlb.0706478

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  20 in total

1.  Engagement of TLR2 reverses the suppressor function of conjunctiva CD4+CD25+ regulatory T cells and promotes herpes simplex virus epitope-specific CD4+CD25- effector T cell responses.

Authors:  Gargi Dasgupta; Aziz Alami Chentoufi; Sylvaine You; Payam Falatoonzadeh; Lourie Ann A Urbano; Ayesha Akhtarmalik; Kimberly Nguyen; Lilit Ablabutyan; Anthony B Nesburn; Lbachir BenMohamed
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-05-17       Impact factor: 4.799

Review 2.  Toll-like receptors and leishmaniasis.

Authors:  Felipe F Tuon; Valdir S Amato; Hélio A Bacha; Tariq Almusawi; Maria I Duarte; Vicente Amato Neto
Journal:  Infect Immun       Date:  2007-12-10       Impact factor: 3.441

3.  Role of the Apt1 protein in polysaccharide secretion by Cryptococcus neoformans.

Authors:  Juliana Rizzo; Débora L Oliveira; Luna S Joffe; Guanggan Hu; Felipe Gazos-Lopes; Fernanda L Fonseca; Igor C Almeida; Susana Frases; James W Kronstad; Marcio L Rodrigues
Journal:  Eukaryot Cell       Date:  2013-12-13

4.  Toll-like receptor 4 (TLR4) polymorphisms in Iranian patients with visceral leishmaniasis.

Authors:  Manoochehr Rasouli; Maryam Keshavarz; Mehdi Kalani; Ali Moravej; Simin Kiany; Parisa Badiee
Journal:  Mol Biol Rep       Date:  2012-10-06       Impact factor: 2.316

5.  Trypanosoma cruzi invades host cells through the activation of endothelin and bradykinin receptors: a converging pathway leading to chagasic vasculopathy.

Authors:  Daniele Andrade; Rafaela Serra; Erik Svensjö; Ana Paula C Lima; Erivan S Ramos; Fabio S Fortes; Ana Carolina F Morandini; Verônica Morandi; Maria de N Soeiro; Herbert B Tanowitz; Julio Scharfstein
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

6.  Specific activation of CD4- CD8- double-negative T cells by Trypanosoma cruzi-derived glycolipids induces a proinflammatory profile associated with cardiomyopathy in Chagas patients.

Authors:  L S A Passos; L M D Magalhães; R P Soares; A F Marques; M do C P Nunes; K J Gollob; W O Dutra
Journal:  Clin Exp Immunol       Date:  2017-07-03       Impact factor: 4.330

7.  Trypanosoma cruzi-induced activation of functionally distinct αβ and γδ CD4- CD8- T cells in individuals with polar forms of Chagas' disease.

Authors:  Fernanda Nobre Amaral Villani; Manoel Otávio da Costa Rocha; Maria do Carmo Pereira Nunes; Lis Ribeiro do Valle Antonelli; Luisa Mourão Dias Magalhães; Janete Soares Coelho dos Santos; Kenneth J Gollob; Walderez O Dutra
Journal:  Infect Immun       Date:  2010-08-09       Impact factor: 3.441

8.  Impaired innate immunity in Tlr4(-/-) mice but preserved CD8+ T cell responses against Trypanosoma cruzi in Tlr4-, Tlr2-, Tlr9- or Myd88-deficient mice.

Authors:  Ana-Carolina Oliveira; Bruna C de Alencar; Fanny Tzelepis; Weberton Klezewsky; Raquel N da Silva; Fabieni S Neves; Gisele S Cavalcanti; Silvia Boscardin; Marise P Nunes; Marcelo F Santiago; Alberto Nóbrega; Maurício M Rodrigues; Maria Bellio
Journal:  PLoS Pathog       Date:  2010-04-29       Impact factor: 6.823

9.  IL-17 produced during Trypanosoma cruzi infection plays a central role in regulating parasite-induced myocarditis.

Authors:  Paulo Marcos da Matta Guedes; Fredy R S Gutierrez; Flavia L Maia; Cristiane M Milanezi; Grace K Silva; Wander R Pavanelli; João S Silva
Journal:  PLoS Negl Trop Dis       Date:  2010-02-16

10.  Glycoinositolphospholipids from Trypanosomatids subvert nitric oxide production in Rhodnius prolixus salivary glands.

Authors:  Felipe Gazos-Lopes; Rafael Dias Mesquita; Lívia Silva-Cardoso; Raquel Senna; Alan Barbosa Silveira; Willy Jablonka; Cecília Oliveira Cudischevitch; Alan Brito Carneiro; Ednildo Alcantara Machado; Luize G Lima; Robson Queiroz Monteiro; Roberto Henrique Nussenzveig; Evelize Folly; Alexandre Romeiro; Jorick Vanbeselaere; Lucia Mendonça-Previato; José Osvaldo Previato; Jesus G Valenzuela; José Marcos Chaves Ribeiro; Georgia Correa Atella; Mário Alberto Cardoso Silva-Neto
Journal:  PLoS One       Date:  2012-10-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.